TEVA Teva Pharmaceutical Industries
- 17.090
- +0.210+1.24%
- 17.090
- 0.0000.00%
Teva Pharmaceutical Industries News
David Abrams Exits Teva Pharmaceutical in Q1 2024, Reflecting Strategic Portfolio Adjustments
Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript)
Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript)
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Israel's Once-Dominant Drugmaker Is Revived by Innovation -- Heard on the Street -- WSJ
By David Wainer Teva Pharmaceutical, one of the world's largest makers of generic drugs, has been in the penalty box with investors for years. The crisis of confidence began in 2016, after the compan
US Stock Nuggets | Popular Chinese securities are booming! Tencent Music's performance surged by nearly 11%; it plans to launch self-developed AI chips next year, and Arm will increase by nearly 60% during the year
Qualcomm's overnight stock price hit a record high, with a cumulative increase of nearly 30% during the year. According to news, the Qualcomm Snapdragon 8 Gen4 chip is being redesigned.
Unusual Options Activity: SNOW, TEVA and Others Attract Market Bets, SNOW V/OI Ratio Reaches 105.9
EST May 13th Closing Delivery - In the last three hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends
Teva Pharmaceutical Industries Options Spot-On: On May 13th, 136.54K Contracts Were Traded, With 875.24K Open Interest
On May 13th ET, $Teva Pharmaceutical Industries(TEVA.US)$ had active options trading, with a total trading volume of 136.54K options for the day, of which put options accounted for 5.11% of the total
Unusual Options Activity: WBD, TEVA and Others Attract Market Bets, WBD V/OI Ratio Reaches 1308.7
EST May 13th Afternoon Delivery - In the last two hours of trading, 6 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends
Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Teva Pharmaceuticals Price Target Raised to $20.00/Share From $19.00 by Piper Sandler
Teva Pharmaceuticals Price Target Raised to $20.00/Share From $19.00 by Piper Sandler
Piper Sandler: Teva Pharmaceutical Indus (TEVA.US) rating was confirmed, adjusted from an increase to an increase rating, and the target price was adjusted from $19.00 to $20.00.
Piper Sandler: Teva Pharmaceutical Indus (TEVA.US) rating was confirmed, adjusted from an increase to an increase rating, and the target price was adjusted from $19.00 to $20.00.
Piper Sandler Reiterates Overweight on Teva Pharmaceutical Indus, Raises Price Target to $20
Piper Sandler analyst David Amsellem reiterates Teva Pharmaceutical Indus with a Overweight and raises the price target from $19 to $20.
These 10 Large Cap Stocks Shined Brightest Last Week (May 5-May 11, 2024): Are They In Your Portfolio?
These large-cap stocks were the best performers in the last week. Are they in your portfolio?Teva Pharmaceutical Industries (NYSE:TEVA) shares surged 16.24% after the company reported mixed Q1 financi
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
Teva Pharmaceuticals Is Maintained at Overweight by Barclays
Teva Pharmaceuticals Is Maintained at Overweight by Barclays
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $20
Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus with a Overweight and raises the price target from $17 to $20.
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 25.47% Barclays $17 → $20 Maintains Overweight 03/08/2024 -12.17% JP Morgan → $14 Upgrades Unde
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Call Transcript
Teva Pharmaceutical Industries First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Analysis
Price Target
No Data
